FDA Advisory Panel Recommends Against Approval Of Novartis Heart Failure ...
The FDA's Cardiovascular and Renal Drugs Advisory Committee voted unanimously (11-0) against approval of the biologics license application (BLA) for serelaxin (proposed trade name Reasanz). The novel drug from Novartis was intended to be used in ...
Novartis Heart Failure Drug Fails to Win FDA Panel BackingBloomberg
FDA panel votes against Novartis drug for acute heart failureReuters
FDA Panel Rejects Novartis Drug for Heart FailureWall Street Journal

all 20 news articles »